Loss of COP9 Signalosome Gene-Containing 2q Region Is Associated with Lenalidomide and Pomalidomide Resistance in Myeloma Patients

MLA

Gooding, Sarah, et al. “Loss of COP9 Signalosome Gene-Containing 2q Region Is Associated with Lenalidomide and Pomalidomide Resistance in Myeloma Patients.” Blood, vol. 138, no. 1, Number 1 Supplement 1, Nov. 2021, p. 458. EBSCOhost, https://doi.org/10.1182/blood-2021-150166.

APA

Gooding, S., Ansari-Pour, N., Kazeroun, M. H., Karagoz, K., Angulo Salazar, M., Fitzsimons, E., Ortiz Estevez, M., Towfic, F., Flynt, E., Pierceall, W. E., Yong, K., Vyas, P., & Thakurta, A. (2021). Loss of COP9 Signalosome Gene-Containing 2q Region Is Associated with Lenalidomide and Pomalidomide Resistance in Myeloma Patients. Blood, 138(1, Number 1 Supplement 1), 458. https://doi.org/10.1182/blood-2021-150166

Chicago

Gooding, Sarah, Naser Ansari-Pour, Mohammad H Kazeroun, Kubra Karagoz, Mirian Angulo Salazar, Evelyn Fitzsimons, Maria Ortiz Estevez, et al. 2021. “Loss of COP9 Signalosome Gene-Containing 2q Region Is Associated with Lenalidomide and Pomalidomide Resistance in Myeloma Patients.” Blood 138 (1, Number 1 Supplement 1): 458. doi:10.1182/blood-2021-150166.